Why the study?
Does intravenous administration of DLL-4 inhibitors induce pulmonary hypertension in patients with solid organ malignancies?
Does intravenous administration of DLL-4 inhibitors induce pulmonary hypertension in patients with solid organ malignancies?
Intravenous DLL-4 inhibitors used for solid organ malignancies are associated with the development of pulmonary hypertension.
May warrant PH monitoring during DLL-4 inhibitor therapy; hypothesis-generating for vascular toxicity mechanisms.
Delta-like ligand 4 (DLL-4) inhibitor drugs are an emerging cancer treatment. In clinical trials for solid organ malignancies, intravenous administration of monoclonal antibodies that inhibit DLL-4 is associated with development of pulmonary hypertension, in the absence of left ventricular dysfunction. Analysis of 13 clinical trials showed that pulmonary hypertension is a complication of DLL-4 inhibition.
No takes yet. Share an insight, caveat, or question.
Besse et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: